| Predictors of response to second-line endocrine therapy for breast cancer. | |
| | |
MedLine Citation:
|
PMID: 9386865 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This study reports on factors predicting response to second-line endocrine therapy in 250 patients with breast cancer for which they were assessable for response by the International Union Against Cancer (UICC) criteria. Clinical details relating to first-line endocrine therapy were available for all patients. We have not included in this study patients who received first-line endocrine therapy but did not or have not yet proceeded to second-line hormone therapy--e.g. died from rapidly progressive disease, started chemotherapy for rapidly progressive disease, or remained in long-term remission on first-line endocrine therapy. One hundred and fifty nine patients (72%) achieved remission (objective response and static disease [OR + SD]) on first-line endocrine therapy with a median duration of 19 months. For second-line endocrine therapy the remission rate was 53% (132/225) with a median duration of 15 months. Tumour grade and oestrogen receptor status of the primary tumour were shown to be independent predictors of response to second-line endocrine therapy while response to first-line endocrine therapy was a predictor of the duration of response to second-line endocrine therapy. In the sub-group of patients who showed OR or SD to both first and second-line therapies, there was no correlation between the time to progression (TTP) on first and second-line therapies. |
| | |
Authors:
|
K L Cheung; P C Willsher; S E Pinder; I O Ellis; C W Elston; R I Nicholson; R W Blamey; J F Robertson |
Related Documents
:
|
9616275 - Retreating recurrent breast cancer with the same cmf-containing regimen used as adjuvan... 8837815 - Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corro... 11368415 - The effect of tamoxifen on breast tumour vascularity. 11268435 - Toremifene as a substitute for adjuvant tamoxifen in breast cancer patients. 7053255 - Phase ii study of doxorubicin and mitomycin in non-small cell bronchogenic carcinoma. 2173095 - Surgical treatment of non-small cell lung cancer by stage. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Breast cancer research and treatment Volume: 45 ISSN: 0167-6806 ISO Abbreviation: Breast Cancer Res. Treat. Publication Date: 1997 Sep |
Date Detail:
|
Created Date: 1998-01-05 Completed Date: 1998-01-05 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8111104 Medline TA: Breast Cancer Res Treat Country: NETHERLANDS |
Other Details:
|
Languages: eng Pagination: 219-24 Citation Subset: IM |
Affiliation:
|
City Hospital, Nottingham, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Aminoglutethimide / therapeutic use Antineoplastic Agents, Hormonal / therapeutic use* Breast Neoplasms / drug therapy, therapy* Female Gonanes / therapeutic use Goserelin / therapeutic use Humans Megestrol Acetate / therapeutic use Middle Aged Nitriles / therapeutic use Ovariectomy Predictive Value of Tests Remission Induction Tamoxifen / therapeutic use Triazoles / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents, Hormonal; 0/Gonanes; 0/Nitriles; 0/Triazoles; 10540-29-1/Tamoxifen; 120511-73-1/anastrozole; 125-84-8/Aminoglutethimide; 51154-23-5/Megestrol Acetate; 65807-02-5/Goserelin; 96346-61-1/onapristone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Bone marrow fibroblastic progenitors in patients with advanced breast cancer.
Next Document: Consistency of patient- and doctor-assessed cosmetic outcome after conservative treatment of breast ...